DDC

DDC Molekülinformation

Englischer Name	Aromatic-L-amino-acid decarboxylase	Anzahl der inverkehr gebrachten Arzneimittel	8
Anzahl der klinischen Arzneimittel	12	Target-Alias	EC:4.1.1.28，EC 4.1.1，DDC，AADC，Dopa Decarboxylase (Aromatic L-Amino Acid Decarboxylase)，Aromatic-L-Amino-Acid Decarboxylase，Aromatic L-Amino Acid Decarboxylase，EC 4.1.1.28，DOPA decarboxylase
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Aromatic-L-amino-acid decarboxylase
Target-Alias	EC:4.1.1.28，EC 4.1.1，DDC，AADC，Dopa Decarboxylase (Aromatic L-Amino Acid Decarboxylase)，Aromatic-L-Amino-Acid Decarboxylase，Aromatic L-Amino Acid Decarboxylase，EC 4.1.1.28，DOPA decarboxylase
Anzahl der inverkehr gebrachten Arzneimittel	8
Anzahl der klinischen Arzneimittel	12
Höchste Forschungs- und Entwicklungsphase	Approved

DDC Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
DDC-H55H6	Human	InsectCells	Human DDC / Dopa Decarboxilase Protein, His Tag (MALS verified)				In den Warenkorb legen

Gesamtmenge1

DDC Molekülhintergrund

Dopa decarboxilase (DDC), also known as aromatic amino acid decarboxylase, is a group II decarboxylase. The enzyme catalyzes the decarboxylation of aromatic L-amino acids to produce the corresponding amines. DDC produces the neurotransmitters dopamine and serotonin from L-Dopa and L-5-hydroxytryptophan, respectively. DDC inhibitors is in clinical use to treat Parkinson's disease(PD), usually co-administrated with L-DOPA. DDC would block peripheral conversion to dopamine and allow a greater percentage of L-DOPA to reach the brain, causing an increase in brain dopamine levels, and reducing the side effects of dopamine-rich blood.

DDC Molekülalias

Aromatic-L-amino-acid decarboxylase,Dopa decarboxilase,AADC

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
VGN-R09	VGN-R09b; VGN-R09	Phase 3 Clinical	Shanghai Vitalgen BioPharma Co Ltd	Aromatic amino acid decarboxylase deficiency; Parkinson Disease	Details
Levodopa/Carbidopa (Hengrui Medicine)	HRG-2010	Phase 3 Clinical	Jiangsu Hengrui Medicine Co Ltd	Parkinson Disease	Details
Buspirone/Carbidopa/Levodopa		Phase 2 Clinical	Universite Laval	Multiple Sclerosis; Spinal Cord Injuries	Details
Levodopa/Carbidopa controlled release tablets-night(WD Pharmaceutical)	WD-1905	Phase 2 Clinical	Shanghai WD Pharmaceutical Co Ltd	Parkinsonian Disorders	Details
Levodopa/Carbidopa controlled release tablets(WD Pharmaceutical)	WD-1603	Phase 2 Clinical	Shanghai WD Pharmaceutical Co Ltd	Parkinson Disease; Parkinsonian Disorders	Details
Ezaladcigene resoparvovec	VY-AADC; VY-AADC01; GZ-404477; AV-201; VY-AADC02	Phase 1 Clinical	University Of California, Voyager Therapeutics Inc	Aromatic amino acid decarboxylase deficiency; Parkinson Disease	Details
AAV2-hAADC gene therapy (UCSF)		Phase 1 Clinical	University Of California San Francisco		Details
Levodopa/Carbidopa (Contera Pharma)	JM-012; CP-012; SOL-707	Phase 1 Clinical	Contera Pharma	Parkinson Disease	Details
RGL-193	RGL-193	Phase 1 Clinical	Shanghai Regenelead Therapies Co Ltd	Parkinson Disease	Details
Carbidopa/oxytriptan	EVX-101	Phase 1 Clinical	Evecxia Therapeutics Inc	Depression; Depressive Disorder	Details
Levodopa/Carbidopa granule(WD Pharmaceutical)	WD-2010	Phase 1 Clinical	Shanghai WD Pharmaceutical Co Ltd	Parkinsonian Disorders	Details
Levodopa/Carbidopa(WD Pharmaceutical)	WD-1804	Phase 1 Clinical	Shanghai WD Pharmaceutical Co Ltd	Parkinsonian Disorders	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Levodopa/Benserazide Hydrochloride		Approved	F. Hoffmann-La Roche Ltd	Madopar	Switzerland	Parkinson Disease	F. Hoffmann-La Roche Ltd	1973-06-27	Parkinson Disease	Details
Eladocagene exuparvovec	PTC-AADC	Approved	National Taiwan University, Ptc Therapeutics Inc	KEBILIDI, Upstaza	EU	Amino Acid Metabolism, Inborn Errors	Ptc Therapeutics International Ltd	2022-07-18	Amino Acid Metabolism, Inborn Errors; Aromatic amino acid decarboxylase deficiency	Details
Levodopa/Carbidopa	DM-1992; AP-CDLD; TPI-926; ND-0612H; PW-4153; LCIG; ABT-SLV187; IPX-203; INP-107(POD™ carbidopa/levodopa); IPX-066; ABT-SLV-187; AP-09004; AP-CD/LD; ND-0612; ND-0680; ND-0612L; IPX-054	Approved	Merck Sharp & Dohme Corp	Patrome, DopaFuse, Sinemet, Numient, Menesit, Duodopa, Vadova, Rytary, Isicom, Duopa, Flexilev, CREXONT, Nacom (imciromab), Nacom retard, Parcopa	United States	Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary	Organon	1975-05-02	Albinism; Albinism, Oculocutaneous; Amblyopia; Amyotrophic Lateral Sclerosis; Aphasia, Broca; Cocaine-Related Disorders; Cognition Disorders; Depressive Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Diabetes Mellitus; Diabetic Retinopathy; Gait Apraxia; Motor Neuron Disease; Parkinson Disease; Parkinson Disease, Postencephalitic; Parkinson Disease, Secondary; Parkinsonian Disorders; Stroke	Details
Benserazide Hydrochloride	Ro-4-4602	Approved			Mainland China	Parkinson Disease; Dyskinesias	Shanghai Yishengyuan Pharmaceutical Co Ltd	1995-01-01	Anemia, Sickle Cell; beta-Thalassemia; Dyskinesias; Parkinson Disease	Details
Foslevodopa/Foscarbidopa	ABBV-951	Approved	Abbvie Inc	VYALEV, Vyalev, Produodopa	Romania, Cyprus, Belgium	Parkinson Disease	Abbvie Deutschland Gmbh & Co Kg, Abbvie Inc, Abbvie Sa		Parkinson Disease	Details
Carbidopa/Entacapone/Levodopa	ELC-200; ODM-101	Approved	Orion Pharma	Stalevo, LECIGon, Trigel, LECIGel, 达灵复	United States	Parkinson Disease	Orion Pharma A/S	2003-06-11	Parkinson Disease	Details
Carbidopa	MK-486	Approved		Lodosyn	United States	Parkinson Disease	Aton	1977-04-25	Orthostatic Intolerance; Parkinson Disease; Postural Orthostatic Tachycardia Syndrome	Details
Carbidopa/Melevodopa	V-1512; GT-1512; CHF-1512; CNP-1512	Approved	Chiesi Farmaceutici SPA	Sirio	Italy	Parkinson Disease	null	2003-01-01	Parkinson Disease	Details